ClinicaliQ Trial Snapshot
- PRostate Cancer Enhanced Diagnosis by Calibration Technology — Recruiting • Oncology • NCT06607783.
- What is being tested: The CARE® Phantom system enables quantitative measurement of apparent diffusion coefficient (ADC) values in prostate tissue during multi-parametric MRI (mpMRI) scans to improve prostate cancer detection accuracy.
- Patient eligibility overview: The trial includes patients undergoing prostate mpMRI assessment, likely those with suspected or at-risk prostate cancer requiring diagnostic imaging evaluation.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The CARE® Phantom system is a medical device system that is being developed has been designed to enable the quantitative measurement of the apparent diffusion coefficient (ADC) in the prostate of patients undergoing a multi-parametric MRI (mpMRI) scan to detect prostate cancer. The final device system will comprise three elements: a calibration mat containing phantoms and embedded monitoring software, a docking station to transfer data from the phantoms, and software as a medical device (SaMD) for calibrating the resulting mpMRI images. In this clinical trial, patients will undergo MRI scanning…
Eligibility Snapshot
- : * Men aged 18 years and older undergoing investigations for PCa. * Standard of Care MRI conducted. * One or more lesions with a Likert score of 3 or above identified on clinical reports. * Planned targeted biopsy within 6 months from the date of clinical care MRI. * Willing and able to provide written informed consent.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.